| | | | | | |
Adult D. immitis worm counts1
| |
|---|
|
Study
|
D. immitis isolate
|
Treatment2
|
Dosage (μg/kg)
|
Days of Tx
|
No. Dogs with worms
|
Worm count range
|
Geometric mean3
|
% reduction
|
Isolate phenotype
|
|---|
|
1
|
Michigan
|
Placebo
|
NA
|
0
|
8 of 8
|
18–32
|
24.4a
|
NA
| |
|
1
|
Michigan
|
Moxidectin
|
3
|
0
|
0 of 8
|
0
|
0.0b
|
100
|
Susceptible
|
|
2
|
MP3
|
Placebo
|
NA
|
0
|
8 of 8
|
21–42
|
35.1a
|
NA
| |
|
2
|
MP3
|
Moxidectin
|
3
|
0
|
0 of 8
|
0
|
0.0b
|
100
|
Susceptible
|
|
3
|
ZoeKY
|
Placebo
|
NA
|
0
|
6 of 6
|
16–36
|
26.2a
|
NA
| |
|
3
|
ZoeKY
|
Moxidectin
|
3
|
0
|
0 of 6
|
0
|
0 b
|
100
|
Susceptible
|
|
4
|
GCFL
|
Placebo
|
NA
|
0
|
3 of 3
|
21–35
|
28.4a
|
NA
| |
|
4
|
GCF
|
Moxidectin
|
3
|
0
|
0 of 3
|
0
|
0b
|
100
|
Susceptible
|
|
5
|
ZoeAL
|
Placebo
|
NA
|
0
|
6 of 6
|
26–47
|
33.0a
|
NA
| |
|
5
|
ZoeAL
|
Moxidectin
|
3
|
0
|
0 of 6
|
0
|
0b
|
100
|
Susceptible
|
|
6
|
JYD-34
|
Placebo
|
NA
|
0, 30, 60
|
8 of 8
|
29–43
|
35.9a
|
NA
| |
|
6
|
JYD-34
|
Moxidectin
|
3
|
0
|
8 of 8
|
20–39
|
29.1b
|
19.0
|
Resistant
|
|
6
|
JYD-34
|
Moxidectin
|
3
|
0, 30, 60
|
8 of 8
|
7–36
|
20.0b
|
44.4
|
Resistant
|
|
7
|
ZoeMO
|
Placebo
|
NA
|
0
|
6 of 6
|
15–32
|
21.2a
|
NA
| |
|
7
|
ZoeMO
|
Moxidectin
|
3
|
0
|
6 of 6
|
2–7
|
5.5b
|
82.7
|
Resistant
|
|
8
|
ZoeLA
|
Placebo
|
NA
|
0
|
6 of 6
|
22–38
|
32.2a
|
NA
| |
|
8
|
ZoeLA
|
Moxidectin
|
3
|
0
|
6 of 6
|
11–26
|
14.8b
|
54.0
|
Resistant
|
|
9
|
AMAL
|
Placebo
|
NA
|
0
|
3 of 3
|
43–48
|
45.0a
|
NA
| |
|
9
|
AMAL
|
Moxidectin
|
3
|
0
|
3 of 3
|
12–25
|
17.3b
|
61.6
|
Resistant
|
-
1Dogs inoculated with 50 infective larvae (L3) on Days −28 to −30
-
2Moxidectin administered as ProHeart® tablets shaved to deliver the exact dose
-
3Within a study, means with different superscripts are significantly different (P < 0.05)
